Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Net Cash Flow came in at $10.6 million in Q1 2026, down 88.82% year-on-year from $94.4 million in Q1 2025, and down 87.5% quarter-over-quarter from $84.5 million in Q4 2025.
Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026) Analysis & Trends
Oculis Holding AG's Net Cash Flow history runs 5 years deep, the most recent figure standing at $10.6 million for Q1 2026.
- On a quarterly basis, Net Cash Flow fell 88.82% year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $56.0 million, a 40.7% decrease from a year earlier, with the FY2025 full-year figure at $72.0 million, up 674.33% from the prior year.
- Net Cash Flow declined to $10.6 million in Q1 2026 per OCS's latest filing, from $84.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $94.4 million in Q1 2025 and bottomed at -$20.1 million in Q2 2025.
- The 5-year median for Net Cash Flow is -$5.7 million (2022), against an average of $14.7 million.
- Across the five-year window, Net Cash Flow plunged 205.76% in 2023 and jumped 1030.89% in 2025, its largest moves.
- Year by year, Net Cash Flow stood at -$8.6 million in 2022, then soared by 219.38% to $10.3 million in 2023, then plunged by 187.95% to -$9.1 million in 2024, then jumped by 1030.89% to $84.5 million in 2025, then sank by 87.5% to $10.6 million in 2026.
- Per Business Quant, the three latest OCS Net Cash Flow figures stand at $10.6 million (Q1 2026), $84.5 million (Q4 2025), and -$18.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 60.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.56 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 84.47 Mn |
| Dec 31, 2025 | 84.47 Mn |
| Sep 30, 2025 | -18.91 Mn |
| Sep 30, 2025 | -18.91 Mn |
| Jun 30, 2025 | -20.10 Mn |
| Jun 30, 2025 | -20.10 Mn |
| Mar 31, 2025 | 94.39 Mn |
| Mar 31, 2025 | 94.39 Mn |
| Dec 31, 2024 | -9.07 Mn |
| Dec 31, 2024 | -9.07 Mn |
| Sep 30, 2024 | -13.33 Mn |
| Sep 30, 2024 | -13.33 Mn |
| Jun 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 22.47 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Dec 31, 2023 | 10.32 Mn |
| Dec 31, 2023 | 10.32 Mn |